首页|Nanomedicine-mediated immunogenic cell death and its combination with immune checkpoint blockade therapy
Nanomedicine-mediated immunogenic cell death and its combination with immune checkpoint blockade therapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
维普
Cancer immunotherapies,which train the natural immune system to specifically kill tumor cells while sparing the healthy cells,have helped revolutionize cancer treatments and demonstrated promising clinical therapeutic benefits for decades.However,the therapeutic outcome of immunotherapies,even for the most successful immune checkpoint blockade(ICB)therapy,remains unsatisfactory in the clinical practice,mainly due to the low immunogenicity of solid tumors and its immunosuppressive tumor microenvironment(TME).Notably,several cancer treatment modalities,including chemotherapy,radiotherapy,and photo-therapy,have been revealed to evoke tumor immunogenicity and reverse immunosuppressive TME via inducing immunogenic cell death(ICD)of tumor cells,which synergistically sensitized tumors to ICB therapy.Nanomedicines have been extensively applied to augment ICD-inducing treatment modalities and potentiate ICB therapeutic efficacy therapy due to the opportune convergence of immunotherapy and nanotechnology.Here,we discuss the recent advances in nanomedicine-mediated ICD and its combination with ICB therapy.
cancer immunotherapynanomedicineimmunogenic cell deathimmune checkpoint blockade
School of Biomedical Sciences and Engineering,South China University of Technology,Guangzhou International Campus,Guangzhou 511442,China
National Engineering Research Center for Tissue Restoration and Reconstruction,Guangdong Provincial Key Laboratory of Biomedical Engineering
Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education,South China University of Technology,Guangzhou 510006,China
National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaOpen Project of Guangdong Province Key Laboratory of Biomedical Engineering
万方数据
维普
